Universität zu Köln

Barta, Stefan K., Xue, Xiaonan, Wang, Dan, Tamari, Roni, Lee, Jeannette Y., Mounier, Nicolas ORCID: 0000-0002-0707-426X, Kaplan, Lawrence D., Ribera, Josep-Maria, Spina, Michele ORCID: 0000-0001-6576-8182, Tirelli, Umberto, Weiss, Rudolf, Galicier, Lionel, Boue, Francois, Wilson, Wyndham H., Wyen, Christoph, Oriol, Albert ORCID: 0000-0001-6804-2221, Navarro, Jose-Tomas, Dunleavy, Kieron, Little, Richard F., Ratner, Lee ORCID: 0000-0003-2744-7294, Garcia, Olga, Morgades, Mireia ORCID: 0000-0003-0295-2534, Remick, Scot C., Noy, Ariela ORCID: 0000-0002-3001-4898 and Sparano, Joseph A. (2013). Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood, 122 (19). S. 3251 - 3263. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical trials to assess treatment-specific factors (type of chemotherapy, rituximab, and concurrent combination antiretroviral [cART] use) and their influence on the outcomes complete response (CR), progression free survival (PFS), and overall survival (OS). In our analysis, rituximab was associated with a higher CR rate (odds ratio [OR] 2.89; P < .001), improved PFS (hazard ratio [HR] 0.50; P < .001), and OS (HR 0.51; P < .0001). Compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted in better CR rates (ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisolone]: OR 1.70; P < .04), PFS (ACVBP: HR 0.72; P = .049; intensive regimens: HR 0.35; P < .001) and OS (intensive regimens: HR 0.54; P < .001). Infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamide (EPOCH) was associated with significantly better OS in diffuse large B-cell lymphoma (HR 0.33; P = .03). Concurrent use of cART was associated with improved CR rates (OR 1.89; P = .005) and trended toward improved OS (HR 0.78; P = .07). These findings provide supporting evidence for current patterns of care where definitive evidence is unavailable.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Barta, Stefan K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Xue, Xiaonan UNSPECIFIED UNSPECIFIED UNSPECIFIED Wang, Dan UNSPECIFIED UNSPECIFIED UNSPECIFIED Tamari, Roni UNSPECIFIED UNSPECIFIED UNSPECIFIED Lee, Jeannette Y. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mounier, Nicolas UNSPECIFIED orcid.org/0000-0002-0707-426X UNSPECIFIED Kaplan, Lawrence D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ribera, Josep-Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Spina, Michele UNSPECIFIED orcid.org/0000-0001-6576-8182 UNSPECIFIED Tirelli, Umberto UNSPECIFIED UNSPECIFIED UNSPECIFIED Weiss, Rudolf UNSPECIFIED UNSPECIFIED UNSPECIFIED Galicier, Lionel UNSPECIFIED UNSPECIFIED UNSPECIFIED Boue, Francois UNSPECIFIED UNSPECIFIED UNSPECIFIED Wilson, Wyndham H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wyen, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Oriol, Albert UNSPECIFIED orcid.org/0000-0001-6804-2221 UNSPECIFIED Navarro, Jose-Tomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Dunleavy, Kieron UNSPECIFIED UNSPECIFIED UNSPECIFIED Little, Richard F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ratner, Lee UNSPECIFIED orcid.org/0000-0003-2744-7294 UNSPECIFIED Garcia, Olga UNSPECIFIED UNSPECIFIED UNSPECIFIED Morgades, Mireia UNSPECIFIED orcid.org/0000-0003-0295-2534 UNSPECIFIED Remick, Scot C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Noy, Ariela UNSPECIFIED orcid.org/0000-0002-3001-4898 UNSPECIFIED Sparano, Joseph A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-472118
DOI:	10.1182/blood-2013-04-498964
Journal or Publication Title:	Blood
Volume:	122
Number:	19
Page Range:	S. 3251 - 3263
Date:	2013
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1528-0020
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language B-CELL LYMPHOMA; ACTIVE ANTIRETROVIRAL THERAPY; ORAL COMBINATION CHEMOTHERAPY; VIRUS-INFECTION STATUS; DOSE-ADJUSTED EPOCH; PHASE-II TRIAL; PLUS RITUXIMAB; INFUSIONAL CYCLOPHOSPHAMIDE; G-CSF; CHOP Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47211